Revelation Biosciences 3Q 2026: EPS ($5.92) — 10-Q Summary

Revelation Biosciences reported a wider net loss for 3Q 2026, with expenses rising due to increased R&D and administrative costs. The company has no revenue. GEM-AKI program and manufacturing costs drove much of the expense growth. Cash reserves were $9.1M, but not enough for a full year of operations. Diluted EPS was ($5.92).

Original reporting
Published Nov 5, 2026, 10:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Revelation Biosciences 3Q 2026: EPS ($5.92) — 10-Q Summary — source image
Decision brief

The 30-second read

$REVBBearishLow
01

Why it matters

The widened loss and limited cash runway suggest heightened execution risk, likely prompting a sell‑off in the stock.

02

Market read

Micro‑cap biotech earnings with cash‑burn concerns; limited impact beyond sector.

03

What to watch

Potential upcoming partnership or grant not disclosed in the filing could mitigate cash concerns.

Relevance 6/10Novelty 7/10Timing: post‑market release

Background

Revelation Biosciences Inc. (REVB) filed its Q3 2026 Form 10‑Q, reporting a net loss of $3.32 M and cash of $9.1 M, insufficient for a full year of operations.

Company-level read

Ticker impact

$REVBBearishMedium confidence
Context

10-Q shows widened net loss and cash runway insufficient beyond one year, new quarterly financials.

Expected impact

likely downward pressure as market prices in the widening loss and cash concerns

Evidence & confidence

Micro‑cap biotech with no revenue; fresh loss figures and cash runway raise execution risk.

Market effects

Highlights cash‑burn pressures in early‑stage biotech sector.

Minimal broader market effect; confined to niche biotech investors.

Low global relevance.

Counterpoint

If the company secures additional financing, the loss may be viewed as a temporary hurdle.

Key entities

  • Revelation Biosciences Inc.

    Micro‑cap biotech reporting Q3 2026 results.

Related articles

$REVBLow

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 SAN DIEGO – November 5, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developi

$REVBMedAI 8/10

Revelation Aiming for Paradigm Shift in Kidney Disease Care

Revelation Biosciences (REVB) is developing Gemini, a drug candidate for acute and chronic kidney disease, post-surgical infections, and severe burns. The company plans to launch a Phase 2/3 study for acute kidney injury later this year, with completion expected in about two years. CEO James Rolke highlights Gemini's potential to reduce inflammation and prevent scar tissue, citing positive pre-clinical and early clinical results. Revelation aims to submit Gemini for FDA approval if the study mee

$REVBMed

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO – August 6, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innov

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.

$LUVUMed

Luvu Brands, Inc.: Luvu Brands Reports First Quarter Fiscal 2027 Results: 10% Net Sales Growth, Wholesale Sales Up 12%

Luvu Brands (LUVU) reported Q1 FY2027 results with net sales up 10% to $6.78M, wholesale sales up 12.3% to $4.72M, and direct-to-consumer sales up 5.3% to $2.06M. Gross profit fell 10.1% to $1.78M due to higher freight and labor costs, resulting in an operating loss of $332K and a net loss of $365K. Cash from operations increased to $120K, and cash reserves were $1.02M.